Investorideas.com newswire, breaking biotechnology and pharma news

Friday, November 18, 2016

#Biotech #Stocks $CANF, $CGIX, $CASC, $CBIO, $CERC, $CANF, $CEMI, $CBAY and $MYAN added to Investor Ideas

#Biotech #Stocks $CANF, $CGIX, $CASC, $CBIO, $CERC, $CANF, $CEMI, $CBAY and $MYAN added to Investor Ideas

Investorideas Updates in #Biotech, #Technology, #Marijuana, #Energy, #Luxury & #Defense


Point Roberts, WA, Delta BC – November 18, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its membership global stock directories in biotech, technology, marijuana, energy, luxury and defense sectors.

Biotech stocks added this week include companies involved in oncology, cancer research, hematology, neuro and psychiatric treatment, point-of-care diagnostics and the treatment of infectious disease.

New technology stocks added include the blockchain and wireless sub-sectors.

Also updated were the marijuana/cannabis/hemp stocks list and a new addition was made to energy stocks with emerging oil and gas exploration and development company Pennine Petroleum Corporation (TSX PNN.V).

The luxury brands stock list now includes a sub-sector for Luxury Jewelry Brands and new companies Birks Group Inc. (NYSE:BGI), DGSE Companies, Inc. (NYSE MKT: DGSE), Movado Group, Inc. (NYSE:MOV) and Signet Jewelers Limited (NYSE: SIG) have been added to both.


Biotech Companies Added:
Can-Fite BioPharma Ltd. (NYSE MKT: CANF), Cancer Genetics, Inc. (NASDAQCM: CGIX), Cascadian Therapeutics, Inc. (NASDAQGS: CASC), Catalyst Biosciences, Inc. (NASDAQCM: CBIO), Cerecor, Inc. (NASDAQCM: CERC), Chembio Diagnostics, Inc. (NASDAQCM: CEMI), Curetis N.V. (Euronext: CURE), Cymabay Therapeutics, Inc. (NASDAQCM: CBAY), Radient Technologies Inc. (TSX:RTI.V) and MYnd Analytics, Inc. (OTC:MYAN)        

Marijuana Companies Added:
Gilla Inc. (OTCQB:GLLA) manufactures, markets and distributes E-liquid, which is the liquid used in vaporizers, E-cigarettes, and other vaping hardware and accessories. E-liquid is heated by the atomizer to deliver the sensation of smoking. Gilla aims to be a global leader in the manufacturing and distribution of E-liquid for the vapor industry. The Company provides consumers with choice and quality across categories and price points. Gilla's product portfolio includes Coil Glaze, The Drip Factory, Surf Sauce, Siren, VaporLiq, Craft Vapes, Craft Clouds, Vape Warriors, Miss Pennysworth's Elixirs, The Mad Alchemist, Replicant and Crown E-liquid brands. Marijuana: Gilla's new brand of CBD E-liquid products will be marketed under the new label "Enriched" and www.enrichedvapor.com

MyDx, Inc. (OTC:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx CannaDx™, AquaDx™ and OrganaDx™ sensors are now commercialized, and the AeroDx™ application is next in line. All Sensors will be compatible with a MyDx App that empowers consumers to test the chemical composition of what they eat, drink and inhale.

Northsight Capital Inc. (OTC:NCAP) is comprised of a portfolio of online marijuana-related websites that are being developed and operated by the company. These sites incorporate many aspects of the marijuana industry. The company provides its audience with a means to stay informed on the industry's most cutting edge marijuana-related innovations and legislation. The company's most dynamic concept, WeedDepot.com, provides consumers with a geo-targeted map directory of medical and recreational dispensaries, head shops, doctors, attorneys and more within the marijuana industry. The Weed Depot app can be downloaded for free at the iTunes Store and Google Play. Weed Depot has an entire platform of content suited for every aspect of advertising and marketing to consumers from all businesses in the cannabis industry. Northsight's current websites include: www.Weeddepot.com, www.420careers.com, www.MJBizwire.com, www.MarijuanaRecipes.com, www.RateMyStrain.com, www.WikiWeed.com, www.MarijuanaMd.com, and www.MarijuanaHealthTips.com

Radient Technologies Inc. (TSX:RTI.V) extracts natural compounds from a range of biological materials using microwave assisted processing ("MAP™"), a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Marijuana November 14 press release announces foray in the fast emerging cannabinoids medical market.

Technology Companies Added:
Arkados Group, Inc. (OTC:AKDS) through its subsidiaries is a global provider of scalable and interoperable Internet of Things (IoT) solutions focused on industrial automation and energy management. The Company's solutions are uniquely designed to drive a wide variety of wireless and powerline communication (PLC)-based products, such as sensors, gateways, video cameras, appliances and other devices. By utilizing the Company's solutions, Arkados' customers can bring numerous sophisticated, full-featured products to market faster at a lower overall development cost. Arkados® is a registered trademark of Arkados Group, Inc.

Coinsilium Group Limited (ISDX:COIN) facilitate the creation and mainstream implementation of blockchain technology products and services from our head-quarters in the global financial hub of London. Coinsilium is a 'first mover' in connecting the mainstream public through the public capital markets, with the blockchain/decentralised
network technology ecosystem and the opportunities this internet evolution brings. Our brand-new Accelerator program Blockchain Space works with brilliant entrepreneurs to help them launch, position and commercialise their crypto and blockchain businesses.

Energy Companies Added:
Pennine Petroleum Corporation (TSX PNN.V) is an emerging oil and gas exploration and development company currently active in Albania and the Canadian provinces of Alberta and Saskatchewan.

Defense Companies Added:
Black Box Corporation (NasdaqGS: BBOX) is a leading technology solutions provider dedicated to helping customers build, manage, optimize, and secure their IT infrastructure. Black Box delivers high-value products and services through its global presence and more than 3,500 team members.  Defense: Black Box is a leading communications system integrator serving all branches of the military. Black Box designs, sources, implements, and maintains complete communications solutions on 6 continents.

Luxury Brand Companies Added:
Birks Group Inc. (NYSE:BGI) is a leading operator of luxury jewelry stores in Canada and Southeastern United States. The Company operates 26 stores under the Birks brand in most major metropolitan markets in Canada , 17 stores in Florida and Georgia under the Mayors brand, one store under the Rolex brand name and two retail locations in Calgary and Vancouver under the Brinkhaus brand. Birks was founded in 1879 and developed over the years into Canada's premier retailer and designer of fine jewelry, timepieces and gifts. Mayors was founded in 1910 and has maintained the intimacy of a family-owned boutique while becoming renowned for its fine jewelry, timepieces and service.

DGSE Companies, Inc. (NYSE MKT: DGSE) wholesales and retails jewelry, diamonds, fine watches, and precious metal bullion and rare coin products through its Charleston Gold & Diamond Exchange and Dallas Gold & Silver Exchange operations. DGSE also owns Fairchild International, Inc., one of the largest vintage watch wholesalers in the country. In addition to its retail facilities in South Carolina and Texas, the Company operates websites which can be accessed at www.dgse.com and www.cgdeinc.com. Real-time price quotations and real-time order execution in precious metals are provided on another DGSE website at www.USBullionExchange.com. Wholesale customers can access the full vintage watch inventory through the restricted site at www.FairchildWatches.com. The Company is headquartered in Dallas, Texas.

Movado Group, Inc. (NYSE:MOV) Movado Group, Inc. designs, sources, and distributes MOVADO®, EBEL®, CONCORD®, ESQ® Movado, COACH®, TOMMY HILFIGER®, HUGO BOSS®, JUICY COUTURE®, LACOSTE® and SCUDERIA FERRARI® watches worldwide, and operates Movado company stores in the United States.

Signet Jewelers Limited (NYSE: SIG) is the world's largest retailer of diamond jewelry. Signet operates approximately 3,600 stores primarily under the name brands of Kay Jewelers, Zales, Jared The Galleria Of Jewelry, H.Samuel, Ernest Jones, Peoples and Piercing Pagoda.

Investorideas.com global stock directories are part of its membership program, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411









Friday, November 4, 2016

#Biotech #Stocks $ATRC, $BMRA Added to #Investorideas

#Biotech #Stocks $ATRC, $BMRA Added to #Investorideas

Investorideas Sector Updates in #Mining & #Biotech


Point Roberts, WA, Delta BC – November 4, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its growing global stock directories within the biotech and mining sectors.

New mining stocks  added are Canadian-based and listed on the TSX Venture Exchange.

New biotech stocks include biotech and life sciences stocks listed on Nasdaq, Euronext, XETRA and Tel Aviv Markets.

Biotech/Life Sciences Companies Added:
AtriCure, Inc. (NasdaqGM:ATRC), Biofrontera AG (XETRA: B8F.DE), Biomerica, Inc. (NasdaqCM: BMRA), Biophytis (Euronext: ALBPS.NX), and Bonus BioGroup Ltd. (Tel Aviv: BONS.TA) 

Mining Companies Added:
Santacruz Silver Mining Ltd. (TSX:SCZ.V; Frankfurt:1SZ:F) is a Mexican focused silver company with a producing silver mine (Rosario); the right to operate a silver mine and mill facility (Veta Grande); an advanced-stage project (San Felipe) and four exploration properties including the Gavilanes property, El Gachi property, Minillas property and Zacatecas properties. The Company is managed by a technical team of professionals with proven track records in developing, operating and discovering silver mines in Mexico. Our corporate objective is to become a mid-tier silver producer.

Nighthawk Gold Corp. (TSX: NHK.V) is a Canadian-based exploration company focused on acquiring and developing gold mineral properties in the Northwest Territories and Northern Ontario. Including the mineral claims and leases of the Colomac Gold Project, Nighthawk's Indin Lake Gold Property comprises a total land package of 222,203 acres in the Indin Lake Greenstone Belt, located approximately 200 kilometres north of Yellowknife, Northwest Territories. Nighthawk also holds a 100% interest in the property known as the Superior Project, which covers 39,015 acres approximately 85 kilometres north of Sault Ste. Marie, Ontario.


Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411







Friday, October 28, 2016

Investorideas Sector Updates in #Mining, #Biotech and #Water #Stocks

#TSX #Mining #Stocks $BRZ.V, $MCI.V, $ORG.V, $SSS.V Added to #Investorideas

Investorideas Sector Updates in #Mining, #Biotech and #Water #Stocks


Point Roberts, WA, Delta BC – October 28, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its growing global stock directories within the mining, biotech and water sectors.

All new mining stocks are Canadian-based and listed on the TSX Venture Exchange.

This week’s water stocks list addition is Forterra, Inc. (NasdaqGM:FRTA), a manufacturer of pipe and pre-cast products used in a variety of water-related infrastructure applications.

New biotech stocks include a biotherapeutics company currently working on hypertension therapies, a clinical stage biotechnology company focused on rare genetic diseases, a molecular diagnostics company, an imaging company focused on early cancer detection and a solutions/service provider for the pharmaceutical market.


Mining Companies Added:
Bearing Resources Ltd. (TSX: BRZ.V), Minnova Corp. (TSX: MCI.V), Orca Gold Inc. (TSX:ORG.V) and Sunvest Minerals Corp. (TSX: SSS.V) 

Water Companies Added:
Forterra, Inc. (NasdaqGM:FRTA) is a manufacturer of pipe and precast products in the U.S. and Eastern Canada for a variety of water-related infrastructure applications, including water transmission, distribution and drainage. Based in Irving, Texas, Forterra employs more than 5,500 people and operates more than 95 facilities, with products available throughout the U.S. and Eastern Canada.

Biotech/Life Sciences Companies Added:
Bellerophon Therapeutics LLC (NasdaqGM: BLPHis a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF) both of which are in Phase 2 development. The Company’s plans call for the completion of further work on the use of INOpulse to treat PH-COPD and PH-IPF during 2016.

Bio Blast Pharma Ltd. (NasdaqGM: ORPNis a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, with a lead drug candidate -- trehalose 90mg/mL IV solution -- in Phase 2 development. Bioblast was founded in 2012.

AlliancePharma Inc. (TSX:APA.V) is a leading solution and service provider to the pharmaceutical market. Today it is a respected name for quality and expertise among pharmacists. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally.

Biocartis Group NV (Brussels: BCART.BRis an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis` proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis has five oncology tests and two infectious disease tests.

Imagin Medical Inc. (CSE:IME, OTC:IMEXF, Frankfurt:DPD2.F) is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411






Tuesday, October 25, 2016

Actinium Pharmaceuticals (NYSE: $ATNM) Initiates Pursuit of Scientific Advice for Iomab-B from the European Medicines Agency

Actinium Pharmaceuticals (NYSE: $ATNM) Initiates Pursuit of Scientific Advice for Iomab-B from the European Medicines Agency

Company is seeking guidance on development plan of Iomab-B for the EU market

Actinium's small and medium-sized (SME) status and orphan designation results in a 100% reduction in fees for scientific advice



NEW YORK - October 25, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has initiated the European Medicines Agency (EMA) Scientific Advice process for Iomab-B. The EMA provides scientific advice to companies regarding the appropriate studies for the development of a medicine. The goal of scientific advice is to facilitate the development and availability of high-quality, effective and acceptably safe medicines, for the benefits of patients.

The Scientific Advice process allows Actinium to dialogue with regulators from the EMA to determine the appropriate development program for Iomab-B in Europe. The EMA created this program to increase the probability of positive outcomes and to reduce the risk of objections during the evaluation of a market-authorization application. Iomab-B, Actinium's lead drug candidate, has been granted orphan designation in the European Union (EU) by the EMA. Iomab-B is intended to be used, upon marketing authorization, in preparing patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are over the age of 55 for a bone marrow transplant (BMT), often referred to as a hematopoietic stem cell transplant (HSCT). Iomab-B is currently in a 150 patient multicenter, pivotal Phase 3 trial that is being conducted in the United States.

Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals said, "We are very excited about the potential of Iomab-B in Europe to address an urgent unmet medical need. We believe Iomab-B is a potentially revolutionary therapy for relapsed or refractory AML patients who are over the age of 55 that could benefit from a bone marrow transplant. This remains a patient population that is drastically underserved on a global scale. Today's initiation for scientific advice, together with our SME status and orphan designation for Iomab-B in the EU, is invaluable as we explore the regulatory pathway for Iomab-B in the EU. We will continue to drive the development of Iomab-B in the U.S. and beyond as we endeavor to bring Iomab-B to all patients that could potentially benefit from this drug candidate."


About Iomab-B
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:
Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.





Wednesday, October 19, 2016

Actinium (NYSE: $ATNM) Announces Acceptance of Actimab-A Data for Poster Presentation at American Society of Hematology Annual Meeting

Actinium (NYSE: $ATNM) Announces Acceptance of Actimab-A Data for Poster Presentation at American Society of Hematology Annual Meeting



NEW YORK - October 19, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that data from the Company’s Actimab-A program, Actinium's most advanced alpha particle immunotherapy program intended for newly diagnosed AML patients over the age of 60, has been selected by the American Society of Hematology (ASH) Program Committee for poster presentation at the 58th Annual Meeting in San Diego, California on December 5, 2016.

Title: Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Abstract: #4050

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Location: San Diego Convention Center, Hall GH

Presentation: December 5, 6:00 PM - 8:00 PM

Abstracts are expected to be available at www.hematology.org on November 3, 2016 at 9:00 am Eastern time. In addition, the abstracts will be published online in the December 3, 2015 supplemental volume of Blood.


About Actimab-A
Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is in a Phase 2 clinical trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which has now been studied in almost 90 patients in four clinical trials.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:
Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.